Organon (OGN) and Lilly (LLY) Expand Migraine Commercialization Agreement to 11 Additional Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
August 20, 2024 7:30 AM EDTThe agreement builds on Organons global product portfolio for conditions that impact women disproportionately. Women are three times more likely to experience migraine than men.i
JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a focus on womens health, announced it has expanded its agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine medicine Emgality® (galcanezumab) in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan,... More
